Related Experiment Video
Updated: Dec 21, 2025
09:09
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
6.4K
Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
Weiwei Wang1, Junting Fan2, Guang Zhu1
1Institute of Pharmaceutical Biotechnology, School of Biology and Food Engineering, Key Laboratory of Spin Electron and Nanomaterials of Anhui Higher Education Institutes, Suzhou University, Suzhou 234000, People's Republic of China.
International Journal of Nanomedicine
|May 20, 2020
Summary
Researchers developed a novel nanoplatform for targeted cancer therapy. This prodrug self-assembled nanoplatform, 2DA-FITC-PTX NPs, shows enhanced tumor targeting and anticancer activity with reduced side effects.
Area of Science:
- Nanomedicine
- Drug Delivery Systems
- Cancer Therapy
Background:
- Targeted prodrugs are crucial for effective tumor therapy.
- Amphoteric small-molecule prodrugs with nanoscale characteristics are of significant interest for self-assembled nano-drug delivery systems (DDS).
Purpose of the Study:
- To develop a prodrug self-assembled nanoplatform integrating targeted small molecules and nano-DDS.
- To enhance tumor targeting ability and reduce systemic toxicity.
Main Methods:
- Conjugation of 2-glucosamine (DA) as a targeting ligand and paclitaxel as an anti-tumor drug via an amino acid group.
- Development of 2-glucosamine-fluorescein-5(6)-isothiocyanate-glutamic acid-paclitaxel (2DA-FITC-PTX NPs) nanoplatform.
- Incorporation of fluorescent dyes (FITC or ICG) for in vivo optical imaging.
Main Results:
- The developed 2DA-FITC-PTX NPs demonstrated a regular structure and excellent targeting ability.
- Enhanced targeting and prolonged retention of the nanoplatform reduced toxicity to normal cells/tissues.
- In vitro and in vivo studies confirmed potent anticancer activity and minimal side effects.
Conclusions:
- This study presents a novel combination of nanomaterials for chemotherapy.
- The developed prodrug-based DDS shows promise for future clinical applications in cancer therapy.
